/
RSS Feed
Poor Ron. He had to get off his bike after less than 2 miles on a gravel ride. The evolocumab is still exerting its effects. We’re thinking critically about the mechanisms of action of his musculoskeletal distress and responding accordingly. We are reducing inflammation, helping him to rebuild muscle, offering items to reduce the risk of atherosclerotic buildup, and something to help to break down any leftover drug in his body based on the pharmacokinetic of the compound. We are hoping he will be back to riding happily in a few weeks! Meanwhile, we also continue on the health benefits of cordyceps and my new friend, the mallow Sida acuta.